Lite Strategy (LITS) Operating Expenses (2010 - 2026)
Lite Strategy (LITS) posted Operating Expenses of $21.6 million for Q1 2026, down 27.65% on a QoQ basis from $29.9 million in Q4 2025, and up 679.02% year-over-year from $2.8 million in Q1 2025.
Analysis
Lite Strategy (LITS) Operating Expenses (2010 - 2026) Analysis & Trends
Lite Strategy has reported Operating Expenses for 17 years, with the latest figure at $21.6 million in Q1 2026.
- On a quarterly basis, Operating Expenses rose 679.02% year-over-year to $21.6 million in Q1 2026; TTM through Mar 2026 was $58.1 million, a 73.12% increase from a year earlier, with the FY2025 full-year figure at $17.5 million, down 65.61% from the prior year.
- Operating Expenses was $21.6 million for Q1 2026 at Lite Strategy, down from $29.9 million in the prior quarter.
- The five-year high for Operating Expenses was $31.3 million in Q1 2022, with the low at $2.8 million in Q1 2025.
- Average Operating Expenses over 5 years is $15.8 million, with a median of $12.5 million recorded in 2023.
- The largest YoY upside for Operating Expenses was 765.46% in 2025 against a maximum downside of 84.84% in 2025.
- Over 5 years, Operating Expenses stood at $23.8 million in 2022, then tumbled by 49.89% to $11.9 million in 2023, then plunged by 71.07% to $3.5 million in 2024, then surged by 765.46% to $29.9 million in 2025, then slipped by 27.65% to $21.6 million in 2026.
- The last three Operating Expenses figures came in at $21.6 million (Q1 2026), $29.9 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 6.54 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 18.20 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 2.09 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 3.00 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.05 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 960.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 2.60 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 367.83 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | 21.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 21.61 Mn |
| Dec 31, 2025 | 29.87 Mn |
| Sep 30, 2025 | 3.74 Mn |
| Jun 30, 2025 | 2.88 Mn |
| Mar 31, 2025 | 2.77 Mn |
| Dec 31, 2024 | 3.45 Mn |
| Sep 30, 2024 | 8.35 Mn |
| Jun 30, 2024 | 18.98 Mn |
| Mar 31, 2024 | 9.83 Mn |
| Dec 31, 2023 | 11.93 Mn |
| Sep 30, 2023 | 10.02 Mn |
| Jun 30, 2023 | 12.54 Mn |
| Mar 31, 2023 | 22.29 Mn |
| Dec 31, 2022 | 23.81 Mn |
| Sep 30, 2022 | 26.95 Mn |
| Jun 30, 2022 | 27.61 Mn |
| Mar 31, 2022 | 31.25 Mn |
| Dec 31, 2021 | 29.46 Mn |
| Sep 30, 2021 | 27.86 Mn |
| Jun 30, 2021 | 22.93 Mn |